glp-1 drugs alzheimer's Could diabetes and weight loss treat disease? GLP-1 drugs failed to slow
Description
PMCID: PMC8419463
Very recently, GLP1 monotherapies have also been applied in the pharmacological management of PCOS, with promising results 32 , which are yet to be consolidated in clinical practice
A tale of two giants Novo Nordisk and Eli Lilly have long been titans in the diabetes care sector, and now they're both carving out new growth narratives in the obesity treatment market
Pharmaceutical GLP-1 agonists offer many health benefits, however their high cost, potential side effects, and weight regain after discontinuation or the requirement for lifetime adherence are major deterrents for many individuals, and highlight the need for more accessible options with improved safety profiles
Diabetic : A person with diabetes
doi:10.1038/nrendo.2010.187 118
